BioWorld Asia

Dec. 22, 2004

Pharmos Crashes On Data From Phase III Brain Study

Once high on Pharmos Corp.'s cannabinoid-receptor drug for brain injury, investors came down hard following news that the compound failed in a pivotal Phase III trial.(BioWorld International) Read More

CAT Wins Court Battle Over Humira; Abbott Logs Appeal

Gene Therapy Boosts Hope For Blood Disease Therapies

Eyeing Cancer Drugs, Aphton Acquiring Igeneon For $81M

Europe Tackles Distinction In Similar Biotech Orphan Drugs

Phytopharm Product, Not Good For Pharma, Aimed At Foods

'Right Time': Bavarian Nordic To Form Cancer Vaccine Unit In U.S.

NicOx Taking Lead CINOD Into Phase III Osteoarthritis Program

Metabolic Jumps, Slides On Trial Data, Analyst Criticism

Santhera Raises Additional EUR7M In Second Closing Of Financing

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Dec. 27, 2024.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for December 24, 2024.

Illustration of neurons with Lewy bodies

Enhanced Cognition: Lewy body dementia phase II pumps stock

BioWorld

Investors will get more details during the International Lewy Body Dementia Conference in Amsterdam late next month, but Wall Street is already buzzing about...

Experimental mRNA gene therapy suppresses preeclampsia in mice

BioWorld MedTech

A gene therapy based on an enhanced lipid nanoparticle (LNP) loaded with vascular endothelial growth factor (VEGF) mRNA could be developed for the treatment of...

Lab glassware and antibodies art concept

Probing bidirectional cancer-autoimmune link can yield new targets

BioWorld Science

Cancer and autoimmunity are “often thought of as being at opposite ends of the immune response,” Ana Anderson told her audience at a joint meeting of the NIH’s...